Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zomedica Pharmaceuticals Corp (NY: ZOM )

0.1202 UNCHANGED
Official Closing Price Updated: 8:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zomedica Pharmaceuticals Corp

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
7 Tempting Stocks to Avoid Until These Key Issues Get Ironed Out
Someday, the challenges and hurdles affecting them could clear up. But for now, consider this group of seven popular plays stocks to avoid. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Penny Stocks to Watch: What’s Going on With ZOM, DARE, PSFE, EFOI and AUUD Today?
Penny stocks are still a hot topic among retail traders and we're covering some of the top ones to watch Wednesday that are on the move. 
Via InvestorPlace
22 Stocks Moving in Wednesday's Pre-Market Session
Gainers Daré Bioscience, Inc. (NASDAQ: DARE) rose 45.2% to $3.08 in pre-market trading after the company reported the FDA approval of XACIATO Vaginal Gel as a treatment... 
Via Benzinga
Exposures Product Safety
2 Big Stock Bets That Are Insiders Are Buying Now
Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy. 
Via InvestorPlace
Zomedica Stock Soars After $71M Pulse Veterinary Acquisition
Zomedica Corp (NYSE:ZOM) has acquired the 
Via Benzinga
Zomedica Stock Looks Tempting Here, But There’s Likely More Downside
Early in 2021, ZOM stock was part of the meme stock trade, but recent catalysts suggest it may be moving toward investment territory. 
Via InvestorPlace
Zomedica Is Languishing Today, but Keep an Eye on This Risky Play
It's a risky play no doubt, but ZOM stock stands to get out of its current rut as a key temporary issue subsides. 
Via InvestorPlace
Zomedica Announces Third Quarter 2021 Financial Results
ANN ARBOR, MI / ACCESSWIRE / November 12, 2021 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health company creating point-of-care diagnostics products for dogs and cats,... 
From Zomedica Corp.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
7 Penny Stocks That Could Have an Explosive Year-End
While meme trends are on the wane, these seven penny stocks still stand to make turbocharged moves higher in the short-term. 
Via InvestorPlace
Exposures COVID-19
Pet Stocks Alert: What Is Going on With PETZ and ZOM Stocks Today?
Speculative pet stocks TDH Holdings and Zomedica are jumping higher in morning trading but investors should be skeptical of the moves. 
Via InvestorPlace
6 of the Hottest Stocks to Pick Up for Less Than $1
These penny stocks are trading for under a dollar, but could change that in the coming months with their strong fundamentals. 
Via InvestorPlace
Stay Away From Zomedica for These 3 Key Reasons
ZOM stock had its best days in early 2021, but now its weak financial performance fully justifies its price weakness. 
Via InvestorPlace
Zomedica Management Finally Delivers Some Good News
Zomedica's acquisition is precisely what was needed to get ZOM stock out of its lethargy. Long-term, it could be a game-changer. Here’s why. 
Via InvestorPlace
Zomedica Stock Will Need More Than a Change in Management to Bounce Back
If the economy falters, past precedent looms ominously for ZOM stock. 
Via InvestorPlace
Topics Economy
Exposures Economy
New CEO and Acquisition Could Breathe New Life Into Zomedica
A turnaround in ZOM stock may happen sooner rather than later as Zomedica undergoes an executive-level change and builds out its business. 
Via InvestorPlace
Zomedica Has Potential, but It’s Far Too Expensive for Now
ZOM stock can be a pet care industry leader, but it needs to make significant improvements before becoming a solid long-term play. 
Via InvestorPlace
The Challenges for Zomedica Continue, But It Still Has Huge Potential
Patience is key with this name, but as it still stands to grab a piece of a multi-billion dollar market, ZOM stock remains worth the risk. 
Via InvestorPlace
3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today
A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need. 
Via InvestorPlace
ZOM Stock: There’s a $71 Million Reason Zomedica Is Gaining Today
ZOM stock is up big today on news of a big merger. The company is acquiring proven vet tech outfit PulseVet in an all-cash deal. 
Via InvestorPlace
Exposures COVID-19
Why Zomedica Shares Are Soaring Today
Zomedica Corp (AMEX:ZOM) is trading significantly higher Friday after the company announced the purchase of Pulse Veterinary Technologies for $70.9 million in cash and stock... 
Via Benzinga
With the Crickets Chirping at Zomedica HQ, Why Buy the Stock?
The only word out of Zomedica in September was its announcement of a new director. That’s not the news ZOM stock needs right now. 
Via InvestorPlace
Even 53 Cents Is Too Much for Zomedica Stock Right Now
At one point, investors loved Zomedica. But until its plans come to fruition, ZOM stock doesn't look like much of a deal. 
Via InvestorPlace
If at First Zomedica Doesn’t Succeed, It Tries, Tries Again
The launch of the Truforma diagnostic platform didn't go perfectly for Zomedica, but holders of ZOM stock still have reason for optimism. 
Via InvestorPlace
Is Zomedica Stock Worth the Risk? Unfortunately It’s Complicated
Zomedica started selling its TRUFORMA vet diagnostic system in March, but ZOM stock won’t see upside until supplier assay issues are resolved. 
Via InvestorPlace
Topics Supply Chain
Exposures Supply Chain
Why Economic Pressure May Build Against Zomedica
Although ZOM stock banks superficially on millennials’ love for pets, brewing economic pressures may undo this catalyst. 
Via InvestorPlace
Zomedica Continues to Execute Poorly
It's been 3.5 months since Zomedica launched Truforma. Unfortunately, due to its poor execution, ZOM stock continues to suffer. 
Via InvestorPlace
Zomedica’s Business Model Is Good, But It’s Still Overpriced
Giving away razors and charging for the blades is often a good idea, but ZOM stock still isn't a good value until it drops closer to 40 cents. 
Via InvestorPlace
The Time to Buy Zomedica Stock May Be Near
After its post-meme collapse, pet healthcare play ZOM stock is still pricey. Wait for it to inch closer to a more optimal entry point. 
Via InvestorPlace
Zomedica Needs to Start Delivering Tangible Results
Zomedica has an interesting story that could work out. However, the company's inability to execute is raising key concerns about ZOM stock. 
Via InvestorPlace
Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now
ZOM stock needs to ramp up sales by a significant margin before investors can get excited about investing in it at this time 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.